← ANALYST RATINGS · TIPRANKS
Immix Biopharma (IMMX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $26.25, the highest $30.00, the lowest $24.00. The average is +228.9% from the last price of $7.98.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $24.00 | Buy | +200.8% | Reiterated | 03.10.26on TipRanks Oct 5 05:10 | +4.0%next day −5.4% · 5 days −9.1% | ↗ |
| Graig Suvannavejh★★★★★★★★★★#381 · hits 48% · avg +21.6% | Mizuho Securities | $26.00 | Buy | +225.8% | Reiterated | 30.09.26on TipRanks 07:10 | −1.1%next day −1.9% · 5 days −10.7% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $21.00 → $30.00+42.9% | Buy | +275.9% | Reiterated | 29.09.26on TipRanks 12:55 | −7.9%next day −1.1% · 5 days −10.5% | ↗ |
| Patrick Dolezal★★★★★★★★★★#1287 · hits 44% · avg +15.1% | LifeSci Capital | $24.00 | Buy | +200.8% | Assigned | 29.09.26on TipRanks 11:55 | −7.9%next day −1.1% · 5 days −10.5% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $27.00 → $30.00+11.1% | Buy | +275.9% | Reiterated | 29.09.26on TipRanks 11:50 | −7.9%next day −1.1% · 5 days −10.5% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $20.00 → $19.00−5.0% | Buy | +138.1% | Assigned | 11.08.26on TipRanks 08:35 | +13.7%next day −1.3% · 5 days +3.2% | ↗ |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | $20.00 → $25.00+25.0% | Buy | +213.3% | Reiterated | 10.08.26on TipRanks 06:27 | +4.2%next day +13.7% · 5 days +12.0% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $23.00 | Buy | +188.2% | Initiated | 09.03.26on TipRanks 04:55 | +8.2%next day +2.8% · 5 days +7.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Immix Biopharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.67 at a price of $10.40 (+146.7%); now: $25.67 at $7.98 (+221.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 5 | 5 | 9 | 8 |
| Buy | 1 | 1 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Immix Biopharma
- CEO: Ilya Rachman
- Employees: 21
- 11400 West Olympic Boulevard, Los Angeles, CA, 90064, US
- www.immixbio.com
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗